James Isernia, MD
Internal Medicine · Myrtle Beach, SCNPI 1144281148
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,134 of the $16,286 with a category attached, or 74.5%. 60 manufacturers reported payments, led by Amgen at 33.7% of the total. Reporting peaked in 2024 at $6,600 and has fallen 74.6% since, to $1,674 in 2025. Among internal medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 781 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$5K
- AbbVie$1K
- Novo Nordisk$1K
- UCB, Inc.$792
- AstraZeneca$718
- Johnson & Johnson$676
- plus $6K from 54 others
Across 22 payments — averaging $2378.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$47K
- AstraZeneca$6K
What the payments were for
- Consulting fees$2,40015%
- Travel & lodging$1,73711%
- Food & beverage$12,13475%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,286 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 170 | $210,492 |
| OzempicSemaglutide | 151 | $196,136 |
| JardianceEmpagliflozin | 124 | $161,147 |
| EliquisApixaban | 162 | $159,642 |
| XareltoRivaroxaban | 47 | $60,033 |
| FarxigaDapagliflozin Propanediol | 50 | $57,093 |
| JanuviaSitagliptin Phosphate | 55 | $55,362 |
| RybelsusSemaglutide | 30 | $46,170 |
| Dupixent PenDupilumab | 12 | $40,363 |
| CreonLipase/Protease/Amylase | 15 | $35,005 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $34,966 |
| Repatha SureclickEvolocumab | 24 | $25,855 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $23,954 |
| TrulicityDulaglutide | 15 | $23,237 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $17,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,157 | $242,306181 claims |
| Lilly USA, LLCMounjaro, Trulicity | $365 | $233,730185 claims |
| Boehringer IngelheimJardiance | $345 | $161,147124 claims |
| PfizerEliquis | $522 | $159,642162 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $718 | $86,02085 claims |
| Johnson & JohnsonXarelto | $676 | $60,03347 claims |
| MerckJanuvia | $278 | $55,36255 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $196 | $42,86457 claims |
| AbbVieCreon, Synthroid | $1,233 | $42,528119 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $603 | $17,30412 claims |
| Astellas Pharma US IncMyrbetriq | $98 | $15,92917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Myrtle Beach
- Edward Botse-BaidooMyrtle Beach$90K
- Sarah AllenMyrtle Beach$17K
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
- Zion LammGreenville$118K
- Bruce GrayGreenville$111K
- Leonard AlsfeldCharleston$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.